Can We Reverse Aging?

Scientists are making unprecedented progress in reversing aging through cellular rejuvenation—a process that mimics the way embryos reset their biological clocks at conception. Pioneered by Shinya Yamanaka’s Nobel-winning discovery of reprogramming adult cells into stem cells, researchers like Juan Carlos Izpisua Belmonte and David Sinclair have refined the technique to avoid cancer risks by using partial, controlled applications of the Yamanaka factors. Sinclair’s work, which restored vision in blind mice without tumor formation, has advanced to human trials for glaucoma and NIOM. Meanwhile, billionaire-backed biotechs like Altos Labs—funded by Jeff Bezos and others—are racing to translate these breakthroughs, using AI-driven virtual cells and human organoids to accelerate research. While some dream of extending life to 150, leaders like Altos CEO Hal Barron emphasize modest, health-focused goals: adding just a few healthy years to life. Yet the ethical and societal implications loom large—how will longer lifespans affect retirement, social security, and workforce dynamics? The episode ultimately questions whether we’re chasing a pharmaceutical fix for aging while ignoring proven, accessible tools like diet, exercise, and social connection—suggesting that true longevity may not be in a lab, but in lifestyle choices we already know.